ArticleClinics and research in hepatology and gastroenterology2026
Association between statins and chronic liver disease progression: A retrospective cohort study.
Article in Clinics and research in hepatology and gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
BACKGROUND AND
objectivesStatins improve portal hypertension and may reduce mortality in cirrhosis, though their impact on chronic liver disease (CLD) progression before developing advanced fibrosis or cirrhosis remains unclear. We aimed to assess the association of statin use with severe liver disease (SLD) outcomes (cirrhosis or HCC) and fibrosis progression in CLD patients.
methodsWe performed a retrospective cohort study of primary care electronic health record data from 2012-2021. Included were patients with CLD, lab inputs for a Fibrosis-4 (FIB-4) calculation and no prior SLD. Analysis 1 assessed the association of statin prescriptions with time to SLD in all patients. Analysis 2 evaluated the association of statin prescriptions with time to high-risk FIB-4 (≥3.25) in patients with baseline FIB-4 <3.25. Unadjusted and adjusted Cox and Weibull regression models were used.
resultsThe cohort included 2,872 CLD patients (median index FIB-4 1.2 IQR: 0.7-1.9) followed for a mean of 5.7 (±2.6) years. 884 (31%) patients received statins and 378 (13%) experienced an SLD outcome. Statin prescription was associated with a lower risk of SLD (adjusted HR 0.51; 95% CI 0.39-0.66). Analysis 2 included 2,547 patients with an index FIB-4 <3.25 followed for a mean of 5.4 (±2.6) years. 855 (34%) patients received statins and 600 (24%) progressed to a FIB-4 ≥3.25. Statin prescription was associated with a lower hazard of progressing to high-risk FIB-4 (adjusted HR 0.36; 95% CI 0.32-0.42).
conclusionIn a primary care population, statin prescriptions were associated with a lower risk of fibrosis progression and SLD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.